These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932 [TBL] [Abstract][Full Text] [Related]
4. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain. Shin SB; Woo SU; Yim H J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351 [TBL] [Abstract][Full Text] [Related]
5. Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations. Wu Y; Zhuo X; Dai Z; Guo X; Wang Y; Zhang C; Lai L Mol Biosyst; 2015 Feb; 11(2):497-505. PubMed ID: 25418836 [TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Choi M; Kim W; Cheon MG; Lee CW; Kim JE Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551 [TBL] [Abstract][Full Text] [Related]
7. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001. Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557 [TBL] [Abstract][Full Text] [Related]
8. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761 [TBL] [Abstract][Full Text] [Related]
9. PLK1 inhibitors: setting the mitotic death trap. Plyte S; Musacchio A Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704 [TBL] [Abstract][Full Text] [Related]
10. Stathmin and microtubules regulate mitotic entry in HeLa cells by controlling activation of both Aurora kinase A and Plk1. Silva VC; Cassimeris L Mol Biol Cell; 2013 Dec; 24(24):3819-31. PubMed ID: 24152729 [TBL] [Abstract][Full Text] [Related]
11. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775 [TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells. Zhang Z; Zhang G; Kong C J Cell Mol Med; 2017 Apr; 21(4):758-767. PubMed ID: 27878946 [TBL] [Abstract][Full Text] [Related]
13. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases. Marxer M; Ma HT; Man WY; Poon RY Oncogene; 2014 Jul; 33(27):3550-60. PubMed ID: 23955083 [TBL] [Abstract][Full Text] [Related]
14. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Lens SM; Voest EE; Medema RH Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634 [TBL] [Abstract][Full Text] [Related]
15. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629 [TBL] [Abstract][Full Text] [Related]
17. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
18. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1). Wäsch R; Hasskarl J; Schnerch D; Lübbert M Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841 [TBL] [Abstract][Full Text] [Related]
19. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374 [TBL] [Abstract][Full Text] [Related]
20. Polo and Aurora kinases: lessons derived from chemical biology. Taylor S; Peters JM Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]